Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
- Author:
Hyungwoo CHO
1
;
Dok Hyun YOON
;
Dong-Yeop SHIN
;
Youngil KOH
;
Sung-Soo YOON
;
Seok Jin KIM
;
Young Rok DO
;
Gyeong-Won LEE
;
Jae-Yong KWAK
;
Yong PARK
;
Min Kyoung KIM
;
Hye Jin KANG
;
Jun Ho YI
;
Kwai Han YOO
;
Won Sik LEE
;
Byeong Bae PARK
;
Jae Cheol JO
;
Hyeon-Seok EOM
;
Hyo Jung KIM
;
Seong Hyun JEONG
;
Young-Woong WON
;
Byeong Seok SOHN
;
Ji-Hyun KWON
;
Cheolwon SUH
;
Won Seog KIM
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2023;55(2):684-692
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods:Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results:A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion:The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.
